Expert Opinion on Emerging Drugs

Future pharmacotherapy in chronic bladder hypersensory conditions
pp. 187-190(4)
Author: Chai, Toby C

Chloroquine-induced nitric oxide as a potential treatment of erectile dysfunction associated with the metabolic syndrome: the science and the fiction
pp. 191-193(3)
Author: Ahmed, Mohamed H

A novel perspective on natural therapeutic approaches in glaucoma therapy
pp. 195-198(4)
Authors: Mozaffarieh, Maneli; Flammer, Josef

Emerging drugs for hepatitis B
pp. 199-217(19)
Author: Zoulim, Fabien

The future of the oral pharmacotherapy of male erectile dysfunction: things to come
pp. 219-228(10)
Authors: Ückert, Stefan; Mayer, Margit E; Stief, Christian G; Jonas, Udo

Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis
pp. 229-252(24)
Authors: Bedlack, Richard S; Traynor, Bryan J; Cudkowicz, Merit E

Emerging therapies for the treatment of patients with advanced neuroendocrine tumors
pp. 253-270(18)
Authors: Chan, Jennifer A; Kulke, Matthew H

Ras as a therapeutic target in hematologic malignancies
pp. 271-284(14)
Authors: Alvarado, Yesid; Giles, Francis J

Luteinising hormone-releasing hormone antagonists in prostate cancer therapy
pp. 285-299(15)
Authors: Msaouel, Pavlos; Diamanti, Evanthia; Tzanela, Marinela; Koutsilieris, Michael

Emerging drugs for the treatment of pancreatic cancer
pp. 301-311(11)
Authors: Van Laethem, Jean-Luc; Marechal, Raphael

Fixed-combination and emerging glaucoma therapies
pp. 313-327(15)
Authors: Woodward, David F; Chen, June

Emerging drug treatments for cystic fibrosis
pp. 329-336(8)
Author: Zeitlin, Pamela L